EVER4010001

FGFR4 inhibitor · EverNov Medicines (Zhuhai Hengqin) Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EVER4010001, covering 2021-01-07 to 2021-01-07. Get the full timeline:

Most recent: Clinical Trial Update: FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

See pricing